Cantor Fitzgerald started coverage on shares of Aravive (NASDAQ:ARAV) in a research note released on Monday morning, The Fly reports. The brokerage issued an overweight rating and a $30.00 target price on the stock.
ARAV has been the subject of several other reports. Wedbush lifted their price target on Aravive from $12.00 to $28.00 and gave the stock an outperform rating in a report on Wednesday, November 20th. Piper Jaffray Companies reaffirmed an overweight rating and issued a $31.00 price objective (down from $36.00) on shares of Aravive in a report on Tuesday, December 3rd. Robert W. Baird upgraded Aravive from a neutral rating to an outperform rating in a research report on Monday, December 2nd. HC Wainwright reissued a buy rating and set a $31.00 target price (up previously from $18.00) on shares of Aravive in a report on Wednesday, November 20th. Finally, Zacks Investment Research raised Aravive from a hold rating to a buy rating and set a $13.00 target price for the company in a report on Thursday, December 5th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. Aravive presently has an average rating of Buy and an average price target of $26.60.
Shares of ARAV stock opened at $11.26 on Monday. The firm has a 50 day moving average price of $7.98 and a two-hundred day moving average price of $6.68. The company has a quick ratio of 7.59, a current ratio of 7.59 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $157.19 million, a PE ratio of -1.06 and a beta of 2.35. Aravive has a 12-month low of $3.07 and a 12-month high of $15.62.
In other Aravive news, Director Srinivas Akkaraju bought 133,333 shares of the stock in a transaction dated Monday, December 2nd. The shares were bought at an average cost of $11.30 per share, with a total value of $1,506,662.90. Also, CEO Jay Shepard sold 4,004 shares of Aravive stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $6.82, for a total transaction of $27,307.28. Insiders own 39.80% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the business. Artal Group S.A. raised its holdings in Aravive by 20.0% in the 2nd quarter. Artal Group S.A. now owns 307,466 shares of the company’s stock valued at $1,845,000 after acquiring an additional 51,197 shares in the last quarter. Renaissance Technologies LLC raised its stake in Aravive by 13.8% in the second quarter. Renaissance Technologies LLC now owns 148,265 shares of the company’s stock valued at $890,000 after purchasing an additional 18,017 shares in the last quarter. BlackRock Inc. raised its stake in Aravive by 5.8% in the second quarter. BlackRock Inc. now owns 173,943 shares of the company’s stock valued at $1,044,000 after purchasing an additional 9,544 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in Aravive by 4.7% during the second quarter. Vanguard Group Inc. now owns 159,034 shares of the company’s stock worth $955,000 after purchasing an additional 7,200 shares during the period. Hedge funds and other institutional investors own 23.82% of the company’s stock.
Aravive, Inc, a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer.
Read More: Stop Order Uses For Individual Investors
Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.